Diabetes drug price war heats up, making treatment more affordable
Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...
Glenmark launches Empagliflozin for diabetes in India under Glempa brand
Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...
Alkem launches low-cost diabetes drug in Indian market
Alkem Laboratories launches generic empagliflozin in India as Empanorm, offering affordable treatment for diabetes and ...
Glenmark Pharma launches generic Empagliflozin in India
Glenmark Pharmaceuticals announced that it has launched generic Empagliflozin, a widely recognized SGLT2 inhibitor, in India.
The Financial Express2d
Alkem Labs launches generic formulation of Boehringer’s diabetes drug in India
Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicted for use in the treatment of type-2 diabetes mellitus.
The Financial Express2d
Glenmark launches generic version of Boehringer’s blockbuster diabetes drug in India
According to the company's statement, these medications are designed to improve glycemic control in adults with Type 2 Diabetes while also reducing cardiovascular outcomes in the patients.
Med price change: Hypertension, diabetes treatment cost to go up
Kolkata: The prices of 53 medicines, including a large number of formulations used to treat diabetes, have been revised ...